What's Happening?
Nexpring Health, a leader in assisted reproductive technology solutions, has announced a strategic investment in May Health, a company developing a novel treatment for polycystic ovary syndrome (PCOS)-related infertility. This investment is part of a €10
million ($11.7 million) financing round, which includes other investors such as Sofinnova Partners, Trill Impact, and Bpifrance. May Health's Anavi™ System, which has received CE Mark certification in Europe, is designed to restore ovulation in women with PCOS who do not respond to first-line therapies. The system is currently undergoing a pivotal U.S. Investigational Device Exemption trial, REBALANCE, to seek FDA marketing authorization.
Why It's Important?
This investment underscores the growing focus on innovative fertility treatments, particularly for conditions like PCOS, which affects 10-13% of women worldwide and is a leading cause of infertility. By supporting May Health, Nexpring Health aims to expand the options available to reproductive medicine professionals and patients, potentially improving outcomes for women struggling with infertility. The development of the Anavi™ System could significantly impact the fertility care landscape by providing a new, minimally invasive treatment option for women who have limited alternatives.
What's Next?
May Health is advancing its REBALANCE trial in the U.S., with more than 15 fertility centers currently enrolling participants. The trial's success could lead to FDA approval, allowing the Anavi™ System to enter the U.S. market. This would provide a new treatment option for women with PCOS-related infertility, potentially improving their chances of conception. Nexpring Health's continued support may also lead to further innovations in fertility care, benefiting both clinicians and patients.
